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Peroxisomal alanine:glyoxylate aminotransferase (AGT) is responsible for glyoxylate
detoxification in human liver and utilizes pyridoxal 50-phosphate (PLP) as coenzyme. The
deficit of AGT leads to Primary Hyperoxaluria Type I (PH1), a rare disease characterized
by calcium oxalate stones deposition in the urinary tract as a consequence of glyoxylate
accumulation. Most missense mutations cause AGT misfolding, as in the case of the
G41R, which induces aggregation and proteolytic degradation. We have investigated the
interaction of wild-type AGT and the pathogenic G41R variant with D-cycloserine (DCS,
commercialized as Seromycin), a natural product used as a second-line treatment of mul-
tidrug-resistant tuberculosis, and its synthetic enantiomer L-cycloserine (LCS). In contrast
with evidences previously reported on other PLP-enzymes, both ligands are AGT revers-
ible inhibitors showing inhibition constants in the micromolar range. While LCS under-
goes half-transamination generating a ketimine intermediate and behaves as a classical
competitive inhibitor, DCS displays a time-dependent binding mainly generating an oxime
intermediate. Using a mammalian cellular model, we found that DCS, but not LCS, is
able to promote the correct folding of the G41R variant, as revealed by its increased spe-
cific activity and expression as a soluble protein. This effect also translates into an
increased glyoxylate detoxification ability of cells expressing the variant upon treatment
with DCS. Overall, our findings establish that DCS could play a role as pharmacological
chaperone, thus suggesting a new line of intervention against PH1 based on a drug repo-
sitioning approach. To a widest extent, this strategy could be applied to other disease-
causing mutations leading to AGT misfolding.
Introduction
Alanine:glyoxylate aminotransferase (AGT, EC 2.6.1.44) catalyzes the conversion of L-alanine and
glyoxylate into pyruvate and glycine in liver peroxisomes, using pyridoxal 50-phosphate (PLP) as coen-
zyme [1]. The deficit of AGT, as a consequence of inherited mutations on the AGXT gene, leads to
accumulation of glyoxylate that is eventually oxidized to oxalate, a metabolic end-product that precipi-
tates as calcium oxalate (CaOx) stones in the kidneys and, in the most severe forms, in the whole
body. This rare condition is named Primary Hyperoxaluria Type I (PH1, OMIM 259900) [2,3]. PH1
patients are currently treated by liver transplantation, a procedure coming with serious side effects, or
by the administration of pyridoxine, a precursor of PLP effective in a minority (30%) of patients [4–6].
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AGT is homodimeric and belongs to the Fold Type I family of PLP-dependent enzymes. The two subunits
interact through an extensive core interface, as well as through an N-terminal extension wrapped over the
neighboring monomer. The active site is made up of residues coming from both subunits and PLP is covalently
bound through a Schiff base linkage with Lys209 [7]. The AGT catalytic mechanism is typical of
PLP-dependent aminotransferases and comprises two half-reactions [1]. In the first one, the α-amino group of
the substrate L-alanine displaces the ε-amino group of Lys209 producing the external aldimine. Then, Lys209
acts as a general base for the 1,3-prototropic shift generating a ketimine intermediate, which hydrolyzes to
pyruvate and pyridoxamine 50-phosphate (PMP) [8]. In the second half-reaction, glyoxylate binds to AGT–
PMP and, through the same steps of the first reaction but in a reverse order, is converted to glycine regenerat-
ing AGT–PLP.
PH1 is an extremely heterogenous disease from a genetic point of view (∼200 pathogenic mutations are
known) [9]. Nevertheless, biochemical and cell biology studies agree upon the view that most missense muta-
tions cause folding defects in AGT that can result in (i) an increased aggregation propensity, either in the
cytosol or inside peroxisomes, (ii) a reduced stability of the dimeric structure, (iii) an increased susceptibility to
proteolytic degradation, and/or (iv) a mislocalization of the protein to mitochondria for mutations co-inherited
with the polymorphic P11L mutation that generates a putative mitochondrial targeting sequence. For these
reasons, PH1 is referred as a misfolding disease [10,11].
The use of small molecules that bind a target protein and enable its proper folding, namely pharmacological
chaperones (PCs), is a promising strategy to treat misfolding diseases. PCs have been successfully applied to
treat lysosomal storage disorders, phenylketonuria, tyrosine hydroxylase deficiency, cystic fibrosis, nephrogenic
diabetes insipidus [12]. In the case of enzymatic deficits, they are usually competitive inhibitors of the target
enzyme. This approach has been also explored in PH1. Aminooxyacetic acid is a well-known AGT inhibitor
behaving as chaperone to rescue some of the most common mutations leading to PH1, but its low specificity
makes it unsuitable for in vivo applications [13]. To identify potential PCs specific for AGT, we looked for
known inhibitors of PLP-enzymes approved for clinical use. Among them, cycloserine (CS) is a cyclic analog of
alanine or serine able to bind many PLP-dependent enzymes including transaminases, racemases and decar-
boxylases [14–19]. The two enantiomers of CS (Figure 1) show different properties. D-cycloserine (DCS) is a
broad-spectrum antibiotic isolated from Streptomyces sp. strains used as a second-line drug in combination
therapies to treat tuberculosis, whose main target is alanine racemase [15,18]. DCS is also used in neurological
studies for its ability to behave as an agonist of NMDA receptors [20]. L-cycloserine (LCS) is the synthetic
enantiomer of CS commonly used as a regulator of lipid metabolism in cellular studies [21]. A common
feature of LCS and DCS is that they are considered irreversible inhibitors of PLP-enzymes, because they form
stable covalent adducts with the cofactor. In some cases, like in branched-chain aminotransferase, alanine race-
mase, and serine palmitoyl transferase [14,15,17], both LCS and DCS behave as inhibitors, although with differ-
ent kinetic properties.
Using a combination of UV-Vis spectroscopy, enzyme kinetics, x-ray crystallography, and mass spectrom-
etry, here we explored the interaction of the two CS enantiomers with wild-type AGT and the G41R pathogenic
variant showing a folding defect leading to an increased tendency to aggregation and degradation [22,23].
Surprisingly, we found that both LCS and DSC behave as reversible competitive inhibitors, although the stereo-
chemistry of the ligand influences inhibition kinetics and mechanism. Studies in a cellular model demonstrate
that DCS, but not LCS, behaves as PC for the G41R variant. The significance of the results obtained for the
general mechanism of inhibition of PLP-enzymes by CS, as well as for the possible future use of the CS chem-
ical scaffold for the development of more specific PCs is discussed.
Materials and methods
Materials
PLP, L-alanine, sodium glyoxylate, rabbit muscle L-lactic dehydrogenase (LDH), β-Nicotinamide adenine
dinucleotide (NADH), isopropyl-β-D-thiogalactoside (IPTG), LCS, DCS and imidazole were all purchased from
Sigma. Ham’s F12 Glutamax medium and Zeocin were purchased from Invitrogen. Geneticin was purchased
from Gibco. Protease Inhibitor Cocktails were purchased from Roche. Water and organic solvents were pur-
chased from Thermo Fisher Scientific. All other chemicals unless otherwise noted, were from Sigma–Aldrich or
Wako.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society2
























































AGT expression and purification
Escherichia coli BL21 cells were transformed with the constructs pAGThisMa and pAGThisG41R-Ma encoding
the most common polymorphic form of AGT (major allele here called wild-type AGT) and the G41R variant
on the background of the major allele, respectively. Expression and purification of the two proteins were per-
formed as already reported [24].
Spectroscopic measurements
Absorbance spectra were registered using a Jasco V-750 spectrophotometer using 1 cm path length quartz cuv-
ettes at a protein concentration of 0.1–20 mM in 0.1 M potassium phosphate buffer (KP), pH 7.4. Wild-type
AGT and the G41R variant concentrations were determined using the previously determined molar absorption
coefficient of 95 400 M−1 cm−1 at 280 nm [24]. PLP content was measured after treatment of the holoenzyme
with 0.1 M NaOH using molar absorption coefficient of 6600 M−1 cm−1 of free PLP at 388 nm. Fluorescence
data were obtained using 1 cm optical quartz cuvettes in a Jasco FP-8200 fluorimeter with excitation and emis-
sion bandwidths of 5 nm. All measurements were performed in KP 0.1 M pH 7.4.
Figure 1. Spectral changes and fluorescence spectra of AGT and the G41R variant upon addition of LCS.
(A) Time-dependent Q5
¶
absorbance spectra of 9 mM wild-type AGT in the absence (black line) or in the presence of 100 mM LCS (dotted line) at the
indicated times. (B) Time-dependent absorbance spectra of 9 mM G41R-Ma variant in the absence (black line) or in the presence of 100 mM LCS
(dotted line) at the indicated times. (C) Fluorescence emission intensity upon excitation at 380 nm for wild-type AGT (—) and the G41R variant (—)
at 1 mM protein concentration. (D) Fluorescence emission intensity upon excitation at 334 nm for wild-type AGT (—) and at 325 nm for the G41R
variant (—) at 1 mM protein concentration. The experiments have been performed in KP 0.1 M pH 7.4 at 25°C.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 3

























































To determine the kinetic parameters of the L-alanine/glyoxylate pair, purified proteins (0.1–0.2 mM) were incu-
bated in the presence of 100 mM PLP in KP 0.1 M pH 7.4 at 25°C at increasing substrate concentrations and a
fixed co-substrate concentration. The reaction was stopped by adding TCA 10% (v/v) and pyruvate production
was measured using a spectrophotometric assay coupled with LDH [25]. Data were fitted to the Michaelis–
Menten equation.
The AGT enzymatic activity in cell lysates was determined by incubating 100 mg of lysate with 0.5 M
L-alanine and 10 mM glyoxylate in the presence of 100 mM PLP for 20 (wild-type AGT) or 50 (G41R variant)
min in KP 0.1 M pH 7.4 at 25°C. Upon addition of TCA 10% (v/v), pyruvate production was measured using
the spectrophotometric assay coupled with LDH.
Inhibition studies
The IC50 for LCS and DCS was determined by incubating each species in the presence of inhibitor at increasing
concentrations (from 1 mM to 50 mM) and then measuring the residual transaminase activity. Each mixture
contained 0.1 mM purified recombinant enzyme, 100 mM PLP, LCS or DCS, 10 mM glyoxylate, in KP 0.1 M
pH 7.4. The reaction was started by the addition of 50 mM L-alanine.
The inhibition constant (KI) of wild-type AGT and the G41R variant for LCS was determined by calculating
the kinetic parameters for L-alanine at various LCS concentrations (from 50 to 400 mM) and by performing a
global (shared-parameter) fitting of the data using a competitive inhibition model.
The slow-binding inhibition kinetics of DCS was evaluated using the progression curve method [26]. A solu-
tion of 0.1 mM wild-type AGT or 0.2 mM G41R variant in the presence of 100 mM PLP was added to reaction
mixtures containing DCS (from 1 mM to 10 mM), L-alanine (250 mM), and glyoxylate (10 mM), in KP 0.1 M
pH 7.4 and incubated at 25°C. At various times, aliquots were collected, the reaction was stopped by the add-
ition of TCA 10% (v/v), and pyruvate produced was measured using LDH as coupled enzyme. Data for each
progression curve were fitted to the integrated rate equation for slow binding inhibitors
[P] ¼ vst þ (v0 þ vs)(1 exp(kobs)= kobs) (1)
where, v0 represent the initial rate, vs the steady-state rate, kobs the apparent first-order rate constant character-
izing the formation of the steady-state enzyme–inhibitor complex. The obtained kobs values were further ana-
lyzed for a one-step association mechanism
kappobs ¼ kappon [I]þ koff (2)
where, koff and kon are the dissociation and association rate constants, respectively. Intercept and slope values,
obtained by linear regression of the kobs versus inhibitor concentration plot (eqn 2), yielded the association and
dissociation rate constants kon and koff, respectively, and the inhibition constant (eqn 3)
KappI ¼ koff =kappon (3)
Kappon was determined from the slope of the plot and then corrected for substrate competition using the
equation





The KtrueI value was obtained from the equation
KtrueI ¼ koff =ktrueon (5)
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society4
























































Crystallization and data collection
Crystallization of the AGT–DCS complex was attempted by co-crystallization using the vapor diffusion
(hanging drop) technique: 1 ml of protein/ligand solution (215 mM AGT; 2 mM DCS; KP 50 mM pH 7.4) was
mixed with an equal volume of reservoir: 10–12% PEG 6K; 5% 2-methyl-2,4-pentanediol (MPD); 0.1 M MES
pH 6.5. Single crystals were cryoprotected by fast soaking into a reservoir solution containing 2 mM DCS and
25% MPD. For the AGT–LCS complex, AGT native crystals grown in the described conditions, with the excep-
tion of DCS, were soaked into a solution containing the reservoir and 20 mM LCS and 20% MPD, before flash
freezing into N2(l) after 20 s. Complete data sets were collected at the ESRF in Grenoble on the ID23-1 beam-
line (operated by the MxCuBE [27] software) at 2.7 and 3.0 Å resolution for the AGT–DCS and AGT–LCS
crystals, respectively. Data were indexed and integrated with XDS [28] and scaled with Aimless [29] within the
CCP4 software suite [30]. Both crystals belonged to the P41212 space group with one monomer in the asym-
metric unit. Initial phases were obtained by molecular replacement using MOLREP [31] and 1.7 Å resolution
structure of AGT as template (pdb: 5F9S [8]). Cycles of model building and refinement were performed with
COOT [32] and REFMAC5 [33], respectively. The models geometry was validated with MolProbity [34] before
deposition in the protein data bank with accession code 6RV0 and 6RV1 for the AGT–DCS co-crystallization
and for the LCS soaked crystal, respectively. Data collection and refinement statistics are reported in
Supplementary Table S1.
UPLC analyses
An amount of 10 mM AGT was inactivated in presence of 2 mM LCS or DCS at 25°C. After 2 h, the reactions
were stopped by the addition of TCA 10% (v/v) and the samples were centrifuged at 18000g for 20 min fol-
lowed by filtration using Millex-GV 0.22 mm filters (Merck MilliPore Ltd). Aliquots were analyzed by UPLC
(Waters UPLC Acquity H class) using a Waters Cortecx C18+, 2.7 mm, 2.1 mm × 150 column equilibrated with
50 mM potassium phosphate pH 2.35 [35]. An isocratic elution was used for 6 min. Each injection was 3 ml
with a flow rate of 0.2 ml/min and absorbance was monitored at 295 nm.
Mass spectrometry (MS)
To identify small molecule reaction products, AGT was inactivated with LCS or DCS as described for UPLC
analyses, and each sample was deproteinized by TCA 10% (v/v). High-resolution mass spectra were recorded
on a Thermo Scientific LTQ Orbitrap electrospray ionization (ESI) ion trap mass spectrometer. Sample
volumes were typically 5 ml under automated injection into a LC system equipped with a C18 column followed
by separation in a methanol : water (50 : 50) mobile phase. The mass spectrometer was set up in full scan
mode, with a range from 150 to 2000 m/z and a resolution of 60 000.
To analyze the LCS- or DCS-inactivated AGT by MS, 10 mg of each protein sample were diluted in 100 ml
of 50 mM ammonium bicarbonate, reduced with 10 mM dithiothreitol (Wako Co.) and then alkylated with
55 mM iodoacetamide (Wako Co.). Overnight digestion was done with Lys-C/Trypsin combo (Promega Co.) in
a 1 : 50 enzyme : protein ratio. Upon stopping the digestion with 1% trifluoroacetic acid, the peptide mixture
was cleaned with desalting C18 tips (StageTip, Thermo), vacuum-centrifuged to dryness, and re-suspended
with 30 ml of 0.1% formic acid in water for LC/MS analysis. Data were collected using a Q-Exactive Plus mass
spectrometer (ThermoFisher Scientific) coupled with Dionex Ultimate 3000RS liquid chromatography system
(ThermoFisher Scientific). An analytical column Zorbax 300SC-18 0.3 × 150 mm, 3.5 mm (Agilent Co.) was
used for sample chromatographic separation. Peptides were separated at a flow rate of 3.5 ml/min using a gradi-
ent of 1–42% ACN (0.1% formic acid) over 60 min.
Raw data files were searched against a composite target/decoy database using SEQUEST HT from Proteome
Discoverer software (PD, v.2.2, Thermo Fisher Scientific). The E. coli protein database was downloaded from
UniProt (UP000000625), combined with contaminants database (cRAP,https://www.thegpm.org/crap) and
target protein sequence AGXT (Uniprot accession P21549). MS2 spectra were searched with ±20 ppm for pre-
cursor ion mass tolerance,±0.1 Da for fragment ion mass tolerance, using trypsin as enzyme, two missed clea-
vages maximum, dynamic modifications for oxidation of methionine and deamidation of glutamine and
asparagine, fixed modification carbamidomethylation of cysteine residues and variable modification of lysine
with PLP (mass shift +231.02911, C8H10NO5P). Label-free quantification based on peak intensity, using
unique and razor peptides, and normalized using total protein amount. Extracted ion chromatogram (XIC) and
isotopic ion distribution were done using Xcalibur software (ThermoFisher Scientific).
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 5

























































The crystal structure of human AGT (PDB ID: 1H0C) (7) has been protonated using the Protonate 3D tool of
MOE 2018.0101 and the docking site was selected using the MOE Site Finder tool. LCS and DCS structures
were docked into the active site of wild-type AGT using the MOE Dock tool. As a first step, Placement gener-
ates a collection of ligand conformations using the bond rotation method. These are then placed in the site by
the Triangle Matcher method and ranked using the London dG scoring function, which estimates the free
energy of binding of the ligand from a given pose. Finally, the Refinement tool is used for energy minimization
of the pocket, before rescoring the poses with Affinity dG, which estimates the enthalpic contribution to the
free energy of binding. The top 30 poses for each ligand were output in the MOE database and analyzed by
visual inspection of the structure.
Cell culture and lysis
Chinese hamster ovary cells stably expressing glycolate oxidase (CHO-GO), and CHO-GO clones expressing
wild-type AGT (CHO-GO-AGT-wt) or the G41R variant (CHO-GO-AGT-G41R), were cultured in Ham’s F12
Glutamax medium supplemented with fetal bovine serum (10%, v/v), penicillin (100 units/ml) and strepto-
mycin (100 mg/ml) at 37°C in a 5% CO2 humidified environment. The expression of AGT and GO was main-
tained by adding G-418 (0.8 mg/ml) and Zeocin (0.4 mg/ml), respectively, to the culture medium. To test the
effects of LCS or DCS, cells were cultured for 7 days in the absence or presence of one of the two CS enantio-
mers at 100 mM concentration. At the end of treatment, cells were harvested and lysed by freeze/thawing (five
cycles) in Phosphate Buffer Saline (PBS), pH 7.2 supplemented with 100 mM PLP and protease inhibitor cock-
tail (Complete Mini, Roche). The whole-cell extract was separated by centrifugation (29,200g, 10 min, 4°C) to
obtain the soluble fraction. Protein concentration in the soluble fraction was measured using the Bradford
protein assay.
Western blot analyses
An amount of 5 mg of soluble cell lysate were loaded on 10% SDS–PAGE, transferred on a nitrocellulose mem-
brane and immunoblotted with anti AGT antibody (1 : 10.000) in 2.5% (w/v) milk in TTBS (50 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 0.1% Tween 20) overnight at 4°C. After three washes in TTBS, the membrane was incu-
bated with peroxidase-conjugated antirabbit immunoglobulin G (IgG) (1 : 10.000) in 5% milk in TTBS for 1 h
at room temperature. Immunocomplexes were visualized by an enhanced chemiluminescence kit (ECL, Pierce
Biotechnology, Rockford, IL).
Glycolate toxicity assay
CHO-GO, CHO-GO-AGT-wt, and CHO-GO-AGT-G41R cells were seeded in Petri dishes in Ham’s F12
Glutamax medium. Where indicated, 100 mM DCS was added to the culture medium. After 6 days cells were
detached and seeded in 96-well plates at a density of 8000 cells/well and exposed to 0.5 mM glycolate. After
24 h of treatment cell viability was assessed by crystal violet staining and results were normalized to that of
controls grown without glycolate, as previously described [36].
Statistical analysis
Experiments have been performed at least in triplicate and in any case the standard error mean (SEM) was
<10%. Statistical analyses were performed by Origin® 7 (Origin Lab) or GraphPad Prism Version 6.0
(GraphPad software, San Diego, CA, U.S.A.).
Results
Binding of LCS to wild-type and mutant AGT
We evaluated the interaction of LCS with wild-type AGT (encoded by the most common major allele) [37] and
the G41R variant (on the background of the major allele) by absorbance spectroscopy. As previously reported,
purified holoAGT displays an absorbance peak at 423 nm and a shoulder at ∼340 nm corresponding to the
oxoenamine and enolimine tautomers of the internal aldimine, respectively [1]. The addition of 100 mM LCS
to wild-type AGT caused the disappearance of the band at 423 nm and the concomitant appearance of a peak
at 334 nm, with a shoulder at 380 nm (Figure 1A). The same spectroscopic changes occurred upon LCS add-
ition to the G41R variant, although in the mutant the band was centered at 325 nm (Figure 1B). Upon
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society6
























































excitation at 380 nm, the AGT–LCS and the G41R–LCS complexes showed a fluorescence emission spectrum
with maximum at 450 nm, typical of the oxime formed between the ligand and PLP [38] (Figure 1C). On the
other hand, the bands a 334 nm and at 325 nm produced a fluorescence emission at 408 nm and 416 nm for
wild-type and mutant AGT, respectively (Figure 1D). These features are indicative of coenzyme forms with a
C40 showing sp3 hybridization [39]. Based on the known mechanisms of interaction of CS with PLP-enzymes,
different hypotheses on the attribution of the 334 and 325 nm bands can be formulated. One of them is the
formation of an inactive hydroxyisoxazole-PMP adduct, as previously reported for alanine racemase and
branched-chain aminotransferase [14,15]. However, we found that the addition of the glyoxylate ketoacid to the
enzyme–LCS complex led to the recovery of the ketoenamine tautomer of the internal aldimine
(Supplementary Figure S1A). This suggests that the band is related to an active form of the coenzyme, such as
PMP or a ketimine intermediate, which undergoes reverse half-transamination in the presence of an amino
acceptor [5,22].
To gain structural details of the AGT–LCS complex, we crystallized wild-type holoAGT and we soaked the
crystals into a solution containing LCS. We collected data at 3.0 Å resolution (Supplementary Table S1). In the
omit map (Figure 2A) we observed a continuous electron density for the Schiff base bond between PLP and
Lys209. After refinement of a model including the internal aldimine, the presence of a weak positive peak near
the C40 of PLP and the low density of the Lys209 side chain suggested the presence of a mixed situation. It
Figure 2. (A) Omit map showing the positive electron density (Fo–Fc map: in green contour level 3.0 sigma — 0.14 e/Å
3) of the
AGT crystal soaked with LCS. (B) Electron density maps after refinement of the final model including PLP internal aldimine
(purple) with an occupancy of 0.75; 2Fo–Fc map (contour 1.5 sigma) in blue. A small positive peak in the Fo–Fc map (in green
contour level 3.0 sigma) is also observed near the PLP C40 atom suggesting that a small amount of PMP may also be present
in the active site. (C) Omit map showing the positive electron density (Fo–Fc map: in green contour level 3.0 sigma — 0.15 e/Å
3)
of the AGT–DCS co-crystallization crystal. Maps were calculated omitting K209, and PLP from the model. (D) Electron density
maps after refinement of the final model including PMP (pink) with an occupancy of 0.75; 2Fo–Fc map (contour 1.5 sigma) in blue Q4
¶
.
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must be clarified that the electron density maps represent the average state of the active site among all the pro-
teins in the crystal. In this case the data suggest that, although the majority of the proteins display the internal
aldimine at the active site, a small percentage of PMP may also be present in the crystal (Figure 2B). However,
given the low resolution of these data, it was not possible to refine neither PMP nor a mixed model with both
the internal aldimine and PMP at different occupancies in the active site, and the final model consisted of the
internal aldimine with an occupancy of 0.75 (i.e. 75% of all the proteins of the crystal).
LCS inhibition mechanism
LCS led to a concentration-dependent drop in transaminase activity, confirming its role as inhibitor, with IC50
values of 50 mM and 136 mM for wild-type and G41R mutant AGT, respectively. Importantly, LCS inhibition
was reversible, since the addition of L-alanine at saturating concentration to a preformed AGT–LCS complex
caused an almost complete recovery (90%) of catalytic activity for both wild-type and variant. The IC50 value
of both species did not change as a function of the incubation time (Supplementary Table S2), thus excluding
the occurrence of a time dependent inhibition. Since LCS undergoes half-transamination, we hypothesized that
it could be a competitive inhibitor for AGT. Indeed, the kinetic parameters of the enzymes for the substrate
L-alanine indicate that the presence of LCS does not affect the value of Vmax, while it causes a concentration-
dependent increase in the KM value. By a global fitting of the data we calculated Ki values of 37 ± 4 mM and 61
± 10 mM for wild-type AGT and the G41R variant, respectively (Figure 3). It should be noted that the Ki value
of the variant is 2-fold higher than that of the wild-type, in line with previous data showing that the Gly41
mutation induces slight changes of the AGT active site architecture [22].
Binding of DCS to wild-type and mutant AGT
The addition of 1 mM DCS to wild-type AGT caused a time-dependent disappearance of the absorbance bands
at 420 and 340 nm and the concomitant appearance of an absorbance band at 370 nm (Figure 4A). The same
band also appeared upon DCS addition to the G41R variant, although in this case an absorbance band at
331 nm was also present, suggesting the formation of two species (Figure 4B). The excitation at 370 nm of the
two enzyme–DCS complexes generated a fluorescence emission spectrum with maximum at 450 nm, indicating
the presence of an oxime intermediate (Figure 4C) [13]. On the other hand, the band at 331 nm of the variant
could be ascribed either to the inactive enolimine tautomer of the internal aldimine, or to the formation of a
ketimine intermediate.
We co-crystallized wild-type AGT in the presence of DCS at 2.5 Å resolution (Supplementary Table S2).
Inspection of the electron density maps in the active site suggested the absence of the Schiff base bond between
Lys209 and the C40 of PLP (Figure 2C). Additional electron density on the opposite side of the C40 atom
further suggested that the internal aldimine had reacted with DCS. After several attempts the best fit for the
observed electron density was PMP, which refined with reasonable B-factors and real space correlation coeffi-
cients (RSCC) values [38,40] when included in the model with a 0.75 occupancy (Figure 2D). Also in this case,
from the density and B-factor analysis the presence of unreacted internal aldimine and/or apo active sites may
not be excluded.
Inhibition mechanism mediated by DCS
Since the absorbance spectra evidenced a time dependent binding of DCS, we determined the IC50 upon incu-
bation of the wild-type enzyme and the G41R variant with the inhibitor at different time points (20 min,
60 min and overnight) at 25°C. The values reported in Supplementary Table S2 show a decreasing IC50 value at
increasing incubation time, a behavior consistent with time-dependent inhibition. Nevertheless, the addition of
L-alanine at saturating concentration to a preformed AGT–DCS complex caused a time-dependent and almost
complete recovery of catalytic activity, while the incubation of the wild-type AGT–DCS and G41R–DCS com-
plexes with PLP alone led to a recovery of activity of 23% and 54%, respectively (Supplementary Figure S2).
These data indicate that DCS inhibition can be completely reversed by the substrate but not by the coenzyme,
thus suggesting that the ligand does not form an irreversibly modified coenzymatic form as reported for other
enzymes of the same family [14,15].
To better investigate the mechanism underlying the time-dependent inhibition mediated by DCS, we deter-
mined the progression curves of the loss of enzymatic activity as a function of time in the presence of the
inhibitor at increasing concentrations (Figure 5A–C). For each curve we calculated the kobs using equation 4. It
should be considered that there are two common mechanisms of slow-binding inhibition. The first, called
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society8
























































Figure 3. Determination of kinetic parameters of wild-type AGT and the G41R variant for L-alanine in presence of LCS.
(A) Cumulative fitting of kinetic parameters of AGT-Ma for L-alanine in absence or presence of LCS at the indicated micromolar
concentrations (eqn 3). (B) Cumulative fitting of kinetic parameters of the G41R variant vs L-alanine in absence or presence of
LCS at the indicated micromolar concentrations (eqn 3). Experiments have been performed in KP 0.1 M pH 7.4 at 25°C.
Figure 4. Spectral changes and fluorescence emission spectra of wild-type AGT and the G41R variant upon addition of DCS.
(A) Time-dependent absorbance spectra of 9 mM wild-type AGT in the absence (black line) or in the presence of 1 mM DCS (dotted lines) at the
indicated times. (B) Time-dependent absorbance spectra of 9 mM G41R in the absence (black line) or in the presence of 5 mM DCS (dotted lines) at
the indicated times. (C) Fluorescence emission spectra of 1 mM wild-type AGT (—) and of the G41R variant (—) in complex with DCS upon
excitation at 370 nm. Experiments have been performed in KP 0.1 M pH 7.4 at 25°C.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 9
























































‘one-step slow binding inhibition’, is described by the scheme: E + I↔ EI and involves the direct formation of
an inactive enzyme-inhibitor complex. The second, called ‘two-step slow binding inhibition’ or ‘isomerization
slow binding inhibition’, is described by the scheme: E + I↔ EI↔ EI* and involves the formation of the
enzyme–inhibitor complex followed by an isomerization generating an inactive complex. To distinguish
between the two models, we plotted the apparent first-order rate constant (kobs) against inhibitor concentration.
As reported in Figure 5B,D, for both wild-type AGT and the G41R variant we observed a linear trend,
Figure 5. Time dependent inhibition of wild-type AGT and the G41R variant by DCS.
(A) Progression curves of wild-type AGT (0.1 mM) in the presence of the indicated concentrations of DCS in KP 0.1 M pH 7.4 at
25°C. (B) Trends of the kobs values obtained using equation 4 as a function of inhibitor concentration. (C) Progression curves of
the G41R variant (0.2 mM) in the presence of the indicated concentrations of DCS in KP 0.1 M pH 7.4 at 25°C. (D) Trends of
the kobs values obtained using equation 4 as a function of inhibitor concentration. (E) Trends of the kobs values for wild-type
AGT (closed symbols) and G41R (open symbols) obtained at 0.1 mM enzyme concentration in the presence of 5 mM DCS, at
increasing substrate concentration (30–500 mM).
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society10
























































indicating that the reaction kinetics follows a one-step slow-binding inhibition mechanism. From the linear fit
of the data to equation 5, we calculated the association and dissociation rate constants, and then the apparent
enzyme–DCS equilibrium dissociation constants (KI
app). To define the modality by which the inhibitor interacts
with the enzyme, we determined the kobs values from progression curves obtained at a fixed saturating concen-
tration of DCS in the presence of increasing concentrations of the substrate. As shown in Figure 5E, the kobs
values decrease as substrate concentration increases. This trend is indicative of a competitive inhibition and
allows to calculate the true KI values from the KI
app. The kinetic constants describing DCS inhibition are sum-
marized in Table 1.
Identification of the wild-type and mutant AGT-cycloserine reaction products
To exclude the occurrence of covalent modifications upon interaction with CS, we performed MS analyses after
limited proteolysis of AGT samples before and after inactivation by LCS or DCS. As expected, the results con-
firmed the presence of a covalent PLP–Lys209 complex in the untreated sample. The same complex was also
present in the AGT–LCS and AGT–DCS sample, although its relative abundance was 7% and 29%, respectively,
as compared with untreated AGT (Supplementary Figure S3), as expected considering that the internal aldi-
mine is converted to other reaction intermediates upon reaction with CS (see below). Thus, AGT inhibition
was not due to the covalent modification of any active site residue.
We then performed UPLC analyses to determine the changes in coenzyme content using a previously setup
method [35]. As reported in Figure 6A, upon reaction with LCS 77% of the initial PLP content of AGT is con-
verted to PMP, in agreement with what observed in the presence of L-alanine and confirming the occurrence of
an half-transamination. On the other hand, upon reaction with DCS only 4% of PLP was converted to PMP,
while 24% eluted as unmodified PLP and the remaining portion eluted as unidentified small peaks appearing at
elution volumes higher than that of PLP. Notably, upon addition of L-alanine to the AGT–DCS complex, 80%
of the coenzyme is converted to PMP. This further confirms that DCS forms a reversible complex with AGT,
which can be displaced by the substrate. We then analyzed the AGT–DCS reaction products by ESI–MS
(Figure 6B). We found (i) peaks at m/z 330.77 and 332.81, which can be attributed to the PLP–DCS external
aldimine, or to a ketimine intermediate generated by a 1,3-prototropic shift, and (ii) peaks at m/z 348.78 and
350.78, which are compatible with the addition of a water molecule to the external aldimine complex leading to
opening of the CS ring. The latter peaks could be ascribed to the external aldimine of PLP with formed
β-aminoserine, an oxime generated by intramolecular rearrangement, or a ketimine between PMP and
β-aminooxypyruvate [17,41]. Our spectroscopic and crystallographic data, along with the reversibility of the
AGT inhibition process, allow to exclude the formation of a covalent PMP-isoxazole complex [14]. Moreover,
no PMP formation is seen by UPLC, thus excluding the occurrence of an half-transamination. Thus, we can
attribute the peaks at m/z 348.78 and 350.78 to an oxime intermediate.
We obtained a qualitatively similar ESI–MS pattern by analyzing the AGT–LCS reaction mixture, although
in this case the intensity of the peaks at m/z 348.78 and 350.78 was lower than that obtained in the AGT–DCS
sample (data not shown). It should be noticed that the obtained m/z values differ by 0.7 D from the expected
values of the nominal mass of the PLP-CS complexes, probably due to already reported random errors that
affect accuracy giving bias in mass measurements [42].
Effects of CS enantiomers on specific activity and expression level of
wild-type AGT and the G41R variant in CHO-GO cells
To test if LCS and/or DCS could act as PCs for AGT variants showing folding defects, we took advantage of a
cellular model made up of CHO cells that overexpress glycolate oxidase (CHO-GO) and recapitulate hepatic
glyoxylate metabolism [43]. In the presence of glycolate in the culture medium, these cells produce glyoxylate
Table 1. Kinetic constants of the time-dependent inhibition of DCS
for wild-type AGT and the G41R variant
Enzyme kon (mM
−1 min−1) koff (min
−1) KI
true (mM)
Wild-type 9.1 ± 0.4 × 10−2 1.6 ± 0.2 × 10−2 175 ± 23
G41R 4.1 ± 0.2 × 10−2 2.8 ± 0.5 × 10−2 682 ± 134
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 11
























































inside peroxisomes and show a strongly reduced viability. CHO-GO cells stably transformed with wild-type
AGT (CHO-GO-AGT-wt) or the G41R variant (CHO-GO-AGT-G41R) were grown in the presence or in the
absence of 100 mM LCS or DCS in the culture medium for 7 days. CS concentration was chosen taking into
account the inhibition constant values, and the use of a pharmacologically relevant ligand concentration, while
the treatment time was that sufficient to allow protein synthesis and folding in the presence of the treating
agent, considering the AGT half-life [44]. Upon cell harvesting and lysis, the soluble fraction of the lysate was
used for experiments aimed at measuring the AGT expression level and specific activity. We found that neither
LCS nor DCS alter the transaminase specific activity and the AGT expression level of CHO-GO-AGT-wt cells
(Figure 6). As for the G41R variant, data obtained with the purified protein indicate that it displays an enzym-
atic activity corresponding to ∼10% that of wild-type AGT (in terms of kcat). When expressed in CHO-GO
cells, the variant showed 10% specific activity and 8% expression level in the soluble fraction, as compared with
the wild type. These data confirm that the variant is endowed with a folding defect that reduces the amount of
soluble and active protein present in the cell, in line with previous evidences indicating a higher tendency to
aggregation induced by the Gly41 mutation [22]. Notably, LCS did not affect the specific activity and the
Figure 6. UPLC and ESI–MS analysis of AGT–CS reaction products.
(A) Coenzyme content of wild-type AGT upon 2 h reaction with 2 mM LCS or DCS at 25°C, as obtained by UPLC analysis. The reaction of the
enzyme with saturating L-alanine was used as positive control. (B) ESI–MS analysis of the wild-type AGT–DCS reaction mixture. The chemical
structures attributed to each peak are shown. See the text for details.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society12
























































expression level of the variant. Since LCS undergoes half-transamination, we also tested the chaperone effect
upon replenishment of LCS in the medium every 24 h. However, we did not notice any change in AGT expres-
sion or activity. On the other hand, DCS induced a statistically significant increase in specific activity
(Figure 7A). To understand whether DCS-induced enhancement of enzymatic activity was dependent on an
increased expression, we analyzed the protein levels CHO-GO-AGT-G41R cells (Figure 7B) and we found that
DCS treatment mildly increases the amount of AGT present in the soluble fraction. These data suggest that the
increased AGT specific activity of CHO-GO-AGT-G41R cells treated with DCS might depend on the capacity
of this enantiomer to specifically bind the misfolded variant and improve its folding efficiency. In agreement
with these results, the treatment with DCS significantly improved the glyoxylate detoxification ability of
CHO-GO cells expressing the G41R variant (Figure 7C), because it increases cell viability upon glycolate treat-
ment. These data confirm that the treatment increases the amount of intraperoxisomal functional AGT able to
metabolize glyoxylate.
Discussion
This work is focused on the analysis of the interaction of AGT, a clinically relevant enzyme involved in the rare
disorder PH1, with the two enantiomers of CS. We performed a spectral, kinetic, and structural characteriza-
tion of the interaction of LCS and DCS with the purified enzyme both in the wild-type form encoded by the
major allele and in a mutant form bearing a folding defect (G41R) on the background of the major allele [22].
We also tested the possible action of LCS and DCS as PCs, i.e. their ability to counteract the effects of the
G41R pathogenic mutation in a cellular model.
Our results indicate that both LCS and DCS do not covalently modify AGT, but bind at the active site and
reversibly inhibit transaminase activity in a competitive way. However, they show a different binding kinetics
and generate a different equilibrium of species. Spectral and kinetic studies agree with LCS behaving as a clas-
sical competitive inhibitor that instantaneously undergoes transamination producing a ketimine and a small
fraction of an oxime intermediate. Crystallographic data are in agreement with the occurrence of a half-
transamination, although we did not obtain other clues about the product(s) and intermediates of the reaction.
Since the AGT crystals were soaked with LCS, it must be considered that the reactivity in the crystal form is
lower with respect to that in solution due to the slower diffusion of the ligand within the crystal lattice.
Therefore, the reaction could have been incomplete, but longer soaking times resulted in non-diffracting crys-
tals. Nevertheless, the UPLC analysis of the coenzyme content upon acidic deproteinization clearly confirms
the formation of PMP, and ESI–MS data show a peak compatible with a ketimine intermediate.
On the other hand, DCS shows a time-dependent binding to wild-type AGT and to the G41R mutant,
leading to spectral changes consistent with the formation of an oxime intermediate associated with the loss of
catalytic activity. The kinetic analysis of the inhibition indicates that it follows a single-step competitive mech-
anism. It is not easy to explain why we did not detect the oxime intermediate in the crystal structure of the
AGT–DCS complex, but we can speculate that it could undergo hydrolysis during the crystallization process or
even radiation damage, as previously reported for other PLP intermediates [8]. UPLC and ESI–MS data
confirm the reversibility of DCS binding and are consistent with the formation of an oxime generated by water
addition to the isoxazolidone ring, followed by intramolecular rearrangement.
Overall, the mechanism that best recapitulates the results on the reaction of AGT with LCS or DCS is
reported in Figure 8. The enzyme in the PLP-form reacts with LCS or DCS forming an external aldimine. In
the case of LCS, a ketimine is formed upon direct deprotonation at Cα and reprotonation at the coenzyme C40.
However, it cannot be excluded that the 1,3-prototropic shift occurs on the external aldimine intermediate
formed upon water addition to the CS ring. Molecular docking analyses of the AGT–LCS complex
(Supplementary Figure S4) indicate that LCS is mainly held in place through a ring stacking interaction with
Tyr260 of the neighboring subunit, and by hydrogen bonds between the exocyclic oxygen and Arg360.
Notably, Lys209 is at 3.5 Å from Cα, thus in a favorable position to perform the 1,3-prototropic shift leading to
ketimine formation. In the case of the AGT–DCS complex, the ligand moiety assumes a different conformation,
with the amino group and the exocyclic oxygen interacting with Arg360. Thus, transaldimination is less
favored, in agreement with the slow kinetics of DCS binding. Moreover, Lys209 is not properly positioned to
act as acid/base catalyst, thus explaining why the AGT–DCS complex undergoes a ring-opening process
mediated by water addition, a process probably favored by the liberation of the carboxylate group that can pref-
erentially interact with Arg360. The latter step generates an intermediate that undergoes an intramolecular
rearrangement producing an oxime of PLP with β-aminooxyserine [7].
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 13
























































Figure 7. Effects of LCS or DCS treatment on specific activity and expression level of AGT. Part 1 of 2
CHO-GO-AGT-wt and CHO-GO-AGT-G41R cells were grown for 7 days in the presence or in the absence of 100 mM LCS or
DCS. At the end of treatment cells were detached, lysed and soluble fraction of each sample used for: (A) AGT enzymatic
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society14
























































The mechanism here described also explains why we noticed that both LCS and DCS are reversible inhibitors
of AGT, as demonstrated by the recovery of activity in the presence of saturating concentrations of the physio-
logical substrate L-alanine. LCS behaves as a classical competitive inhibitor, and thus can be displaced by the
substrate when it is present at saturating concentration in the overall transamination reaction mixture. In add-
ition, the ketimine formed with LCS is supposed to be in equilibrium with the external aldimine intermediate,
thus explaining the recovery of activity when the AGT–LCS complex is preformed. A similar behavior has been
already reported for competitive inhibitors of alpha-galactosidase A in Fabry disease [45,46] as well as for imi-
nosugar derivatives as glucocerebrosidase inhibitors in Gaucher disease [47,48]. As for the oxime intermediate
generated with DCS, it is not difficult to hypothesize that the α-amino group of L-alanine could compete with
the N atom of ligand moiety for the binding to the C40 of PLP and displace the inhibitor, thus leading to a
recovery of catalytic activity. These findings get a new light on the mechanism underlying the action of LCS
and DCS, because both molecules have been always considered as irreversible inhibitors of PLP-enzymes
[15,49]. However, it should be pointed out that experiments aimed at testing the regain of activity induced by
the substrate have not been performed in all previous studies.
Figure 7. Effects of LCS or DCS treatment on specific activity and expression level of AGT. Part 2 of 2
activity determination. Specific activity of AGT in CHO-GO-AGT-wt control cells (192.54 ± 12.68 nmoles of pyruvate/min/mg
protein) was assumed as 100%. Data represent mean ± SEM (n = 4). * P < 0.005, Student’s t-test; (B) AGT expression level
quantification. AGT levels in CHO-GO-AGT-wt control cells was assumed as 100%. (C) Representative western blot of AGT
expression levels in the indicated cells clones. For each gel, the corresponding Ponceau staining of the total lysate is also
shown as loading control. (D) Indirect glycolate toxicity assay. Histogram representative of cell viability after 24 h of treatment
with 0.5 mM glycolate expressed as percentage with respect to untreated cells. Six replicates have been measured for each
sample. CHO-GO and CHO-GO-AGT-wt cells represent the negative and positive control, respectively. The images are
representative of one out of three separate experiments. Data represent mean ± SEM (n = 4).
Figure 8. Proposed reaction mechanism of AGT with LCS or DCS.
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The reversible behavior of LCS and DCS prompted us to test their action as PCs in a cellular model recapitu-
lating the metabolic alterations typical of patients affected by PH1, a disease where misfolding is one of the
main factors underlying the effects of pathogenic mutations in AGT. We used as models cells expressing wild-
type AGT and cells expressing the G41R variant, which shows a folding defect giving rise to an increased ten-
dency to aggregation and to intracellular degradation [22,23]. We found that only DCS is able to partly rescue
for the pathogenic G41R mutation, leading to a recovery of catalytic activity paralleled by an increased portion
of protein present in the soluble fraction. This can be understood considering that LCS behaves as a substrate,
generating PMP, which can rapidly dissociate from the G41R variant inside the cell. On the other hand, the
slow binding of DCS could allow the ligand to remain bound at the active site for a time long enough to
promote the correct folding of the protein. It should be mentioned that DCS is a natural product used to treat
resistant Mycobacterium tuberculosis infections as well as neurological disorders since it is a potent NMDA
receptor agonist [50]. These findings strongly support the use of DCS as a valuable template for the synthesis
of PCs for PH1. The preparation and biological evaluation of improved analogs is currently ongoing in our
laboratories.
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